Literature DB >> 1486812

Long-term follow-up of central serous retinopathy in 150 patients.

J Castro-Correia1, M F Coutinho, V Rosas, J Maia.   

Abstract

To study the evolution of the retinal pigment epithelial lesions in the central serous retinopathy, the authors studied 150 patients with ages between 20 and 49 years at the first examination, during periods varying between 6 months and 14 years. It was found a greater incidence of the disease in the males (83.3%); bilaterality in 23.3%; only one point of leakage in 62.7%; 3 different types of diffusion (inkblot 71.4%; mushroom 23.8%; with serous pigment epithelial detachment 4.9%). The final visual acuity was < 20/40 in a quarter of the cases and the frequency of the recurrences was 30%. The laser treatment did not influence the recurrences. In 50 patients with a follow-up superior to 3 years, 8 (16%) developed lesions similar to those described as diffuse retinal pigment epitheliopathy with visual field defects and subnormal EOG. Actuarial calculus suggests that 50% of the patients may get the most severe and extensive form of the disease after 12 years of evolution. The results allow to conclude that the diffuse retinal pigment epitheliopathy is only the terminal state of the most severe cases of central serous retinopathy.

Entities:  

Mesh:

Year:  1992        PMID: 1486812     DOI: 10.1007/bf00169099

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  10 in total

1.  Bullous retinal detachment. An unusual manifestation of idiopathic central serous choroidopathy.

Authors:  J D Gass
Journal:  Am J Ophthalmol       Date:  1973-05       Impact factor: 5.258

2.  Long-term follow-up of central serous retinopathy.

Authors:  M Nanjiani
Journal:  Trans Ophthalmol Soc U K       Date:  1977-09

3.  Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy.

Authors:  D M Robertson; D Ilstrup
Journal:  Am J Ophthalmol       Date:  1983-04       Impact factor: 5.258

4.  [Diffuse retinal epitheliopathy and central serous chorioretinopathy].

Authors:  D Cohen; A Gaudric; G Coscas; G Quentel; M Binaghi
Journal:  J Fr Ophtalmol       Date:  1983       Impact factor: 0.818

5.  Experience with nontreatment of central serous choroidopathy.

Authors:  M L Klein; E M Van Buskirk; E Friedman; E Gragoudas; S Chandra
Journal:  Arch Ophthalmol       Date:  1974-04

6.  Direct and indirect laser photocoagulation of central serous choroidopathy.

Authors:  R C Watzke; T C Burton; R F Woolson
Journal:  Am J Ophthalmol       Date:  1979-11       Impact factor: 5.258

7.  Argon laser photocoagulation in the treatment of central serous retinopathy.

Authors:  P Leaver; C Williams
Journal:  Br J Ophthalmol       Date:  1979-10       Impact factor: 4.638

8.  Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy.

Authors:  L A Yannuzzi; J L Shakin; Y L Fisher; M A Altomonte
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

9.  Long-term follow-up of central serous chorioretinopathy.

Authors:  C M Gilbert; S L Owens; P D Smith; S L Fine
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

10.  Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography.

Authors:  R Levine; A J Brucker; F Robinson
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

  10 in total
  34 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Finasteride for chronic central serous chorioretinopathy.

Authors:  Farzin Forooghian; Annal D Meleth; Catherine Cukras; Emily Y Chew; Wai T Wong; Catherine B Meyerle
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

4.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

5.  Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy.

Authors:  Pawan Gupta; Vishali Gupta; M R Dogra; Ramandeep Singh; Amod Gupta
Journal:  Int Ophthalmol       Date:  2009-01-30       Impact factor: 2.031

6.  Retinal pigment epithelium apertures as a late complication of longstanding serous pigment epithelium detachments in chronic central serous chorioretinopathy.

Authors:  Claudio Iovino; Jay Chhablani; Deepika C Parameswarappa; Marco Pellegrini; Giuseppe Giannaccare; Enrico Peiretti
Journal:  Eye (Lond)       Date:  2019-07-02       Impact factor: 3.775

7.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

8.  Serum erythropoietin levels in patients with central serous chorioretinopathy.

Authors:  Burak Turgut; Nevin Ilhan; Fatma Yayla Uyar; Ulku Celiker; Tamer Demir; Suleyman Serdar Koca
Journal:  Eye Brain       Date:  2010-06-05

9.  Serum dehydroepiandrosterone sulphate, total antioxidant capacity, and total oxidant status in central serous chorioretinopathy.

Authors:  Fatih Mehmet Türkcü; Harun Yüksel; Hatice Yüksel; Alparslan Sahin; Yasin Cinar; Abdullah Kürşat Cingü; Muhammed Sahin; Ihsan Caça
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-06-08       Impact factor: 3.117

10.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.